Effects of denosumab in patients with bone metastases with and without previous bisphosphonate exposure
Jean‐Jacques Body(Université Libre de Bruxelles), Karim Fizazi(Institut Gustave Roussy), Julie R. Gralow(American Society of Clinical Oncology), Guenther G. Steger(Mount Vernon Hospital), Guozhi Gao(Amgen (United States)), Howard Yeh(Covance (United States)), Allan Lipton(American Society of Clinical Oncology)
Cited by 120
Related Papers
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
|Journal of Clinical Oncology|2016|1.6k
Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study
|Journal of Clinical Oncology|2010|1.6k